<DOC>
	<DOC>NCT02443467</DOC>
	<brief_summary>This was an open-labeled, multi-center, prospective, non-comparative study of the safety of Herceptin (trastuzumab) used as an adjuvant therapy in patients with early breast cancer who had previously received antracycline therapy before or after surgery.</brief_summary>
	<brief_title>A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female patients &gt; or = 18 years of age Human Epidermal Growth Factor Receptor 2 (HER2)neu overexpression Previously treated with adjuvant antracycline containing chemotherapy Left Ventricular Ejection Fraction (LVEF) &gt; 50% Eastern Cooperative Oncology Group (ECOG) score &lt; or = 2 Life expectancy &gt; or = 12 weeks Left Ventricular Ejection Fraction (LVEF) &lt; 50% Advanced pulmonary disease Severe dyspnea Abnormal laboratory results within 14 days prior to registration Peripheral neuropathy Presence of Central Nervous System (CNS) metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>